Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | TDP2 | O95551 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10677017 | 0.85 | HTT (0.48) | ALDH1A1MAPTHTTKDM4EGAA | |
| SCHEMBL11790909 | 0.74 | MAPT (0.38) | ALDH1A1MAPTHTTKDM4EGAA | |
| SCHEMBL354474 | 0.74 | ALDH1A1 (0.48) | ALDH1A1MAPTHTTKDM4EGAA | |
| SCHEMBL9391999 | 0.73 | MAPT (0.36) | ALDH1A1MAPTHTTKDM4EGAA | |
| SCHEMBL10693199 | 0.73 | MAPT (0.39) | ALDH1A1MAPTKDM4EGAAMEN1 | |
| SCHEMBL13341066 | 0.73 | MAPT (0.36) | ALDH1A1MAPTHTTKDM4EGAA | |
| SCHEMBL30099690 | 0.72 | ALDH1A1 (0.55) | ALDH1A1MAPTKDM4EGAAMEN1 | |
| SCHEMBL11789560 | 0.72 | CYP1A2 (0.45) | ALDH1A1MAPTKDM4EGAAHPGD | |
| SCHEMBL1303947 | 0.72 | ALDH1A1 (0.39) | ALDH1A1MAPTHTTKDM4EGAA | |
| SCHEMBL14441609 | 0.71 | ALDH1A1 (0.44) | ALDH1A1MAPTHTTKDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088783-B2 | MAPK/ERK kinase inhibitors | DONG QING (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088783-B2 | MAPK/ERK kinase inhibitors | DONG QING (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088783-B2 | MAPK/ERK kinase inhibitors | DONG QING (US) | 2012-01-03 | — | — | US | disclosed |
| US-20110190261-A1 | MAPK/ERK Kinase Inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-08-04 | — | — | US | disclosed |
| US-20110190261-A1 | MAPK/ERK Kinase Inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-08-04 | — | — | US | disclosed |
| US-20110190261-A1 | MAPK/ERK Kinase Inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-08-04 | — | — | US | disclosed |
| US-7943626-B2 | Substituted 1,3-dialkyl-2,4-dioxo-6-(pyridylamino)-1,2,3,4-tetrahydropyrimidine-5-hydroxamic acid inhibitors of MAPK/ERK kinase | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-17 | — | — | US | disclosed |
| US-7943626-B2 | Substituted 1,3-dialkyl-2,4-dioxo-6-(pyridylamino)-1,2,3,4-tetrahydropyrimidine-5-hydroxamic acid inhibitors of MAPK/ERK kinase | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-17 | — | — | US | disclosed |
| US-7943626-B2 | Substituted 1,3-dialkyl-2,4-dioxo-6-(pyridylamino)-1,2,3,4-tetrahydropyrimidine-5-hydroxamic acid inhibitors of MAPK/ERK kinase | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-17 | — | — | US | disclosed |
| US-20100204471-A1 | MAPK/ERK KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-12 | — | — | US | disclosed |
| WO-2008140553-A2 | MAPK/ERK KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-20 | — | — | WO | disclosed |
| US-20080125437-A1 | MAPK/ERK KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. | 2008-05-29 | — | — | US | disclosed |
| US-20080125437-A1 | MAPK/ERK KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. | 2008-05-29 | — | — | US | disclosed |
| US-20080125437-A1 | MAPK/ERK KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. | 2008-05-29 | — | — | US | disclosed |
| US-5162327-A | PYRIMIDINETRIONE DERIVATIVES, AGENTS CONTAINING THEM AND THEIR USE AS AGENTS FOR COMBATING PESTS | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-11-10 | — | — | US | disclosed |
| US-4762830-A | 5-(azolyloxyphenylcarbamoyl)barbituric acid derivatives as anthelmintics | CIBA-GEIGY CORPORATION (US) | 1988-08-09 | — | — | US | disclosed |
| US-4753940-A | PARASITICIDE, ANTHELMINTIC | CIBA-GEIGY CORPORATION (US) | 1988-06-28 | — | — | US | disclosed |
| US-4748178-A | 5-(pyridyloxy- or pyridylthio-phenyl)carbamoyl barbituric acid derivatives | CIBA-GEIGY CORPORATION (US) | 1988-05-31 | — | — | US | disclosed |
| US-4602912-A | SYNTHETIC PYRETHROID;FOR KERATINOUS MATERIAL | CIBA-GEIBY CORPORATION (US) | 1986-07-29 | — | — | US | disclosed |
| US-4503100-A | 5-PHENYLCARBAMOYLBARBITURIC ACID AND SYNTHETIC PYRETHROID | CIBA-GEIGY CORPORATION (US) | 1985-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190261-A1 | MAPK/ERK Kinase Inhibitors | MAPK1, MAPK4, MAPK6 | ALDH1A1 1803/4885MAPT 2201/4885HTT 4226/4885 |
| US-20100204471-A1 | MAPK/ERK KINASE INHIBITORS | MAPK1, MAP3K1, MAP3K7 | ALDH1A1 2921/4885MAPT 1465/4885HTT 4834/4885 |
| US-20080125437-A1 | MAPK/ERK KINASE INHIBITORS | MAPK1, MAP3K1, MAP3K7 | ALDH1A1 2921/4885MAPT 1465/4885HTT 4834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.